A Study to Evaluate Precision Pharmacogenomics in Cancer Patients
Tab Title Description
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
- Scottsdale/Phoenix, Arizona: 19-002006
NCT ID: NCT04067960
Sponsor Protocol Number: 19-002006
About this study
THe purpose of this study is to examine the current and (potential) future therapeutic relevance of pharmacogenomics (PGx) testing for a cohort of cancer patients in order to improve quality of life (QOL) in patients receiving clinical care at Mayo Clinic.
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
- Patient enrolled to Mayo Clinic IRB: 18-000326
- Patients with stage 3 or 4 breast, colorectal, prostate/GU, pancreato-biliary, brain, melanoma, and ovarian cancer.
- Individuals have agreed to participate and signed the study informed consent form.
- Patients with cancer types other than the ones mentioned above
- Patient with psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent.
- Previous PGx testing with results available within Mayo Clinic EMR.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
|Mayo Clinic Location
Mayo Clinic principal investigator
Niloy Jewel Samadder, M.D.
Open for enrollment
Cancer Center Clinical Trials Referral Office
Publications are currently not available